Xenetic Biosciences Inc (XBIO)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Xenetic Biosciences Inc (XBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013528
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Xenetic Biosciences Inc (Xenetic), formerly General Sales & Leasing, Inc., is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of biologic drugs and innovative orphan cancer drugs. The company’s pipeline products include ErepoXen, Virexxa and OncoHist. Its lead product candidate, ErepoXen, is a polysialylated form of erythropoietin (EPO) which is used to treat anemia in pre-dialysis patients with chronic kidney disease; Virexxa and OncoHist are used for the treatment of progesterone receptor negative endometrial cancer and refractory acute myeloid leukemia. Xenetic works in collaboration with other organization such as Shire and Pharmsynthez to formulate a new series of polysialylated blood coagulation factors. The company has operational presence in the UK. Xenetic is headquartered in Lexington, Massachusetts, the US.

Xenetic Biosciences Inc (XBIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Xenetic Biosciences Acquires Rights to Virexxa from Kevelt 11
Partnerships 12
Xenetic Biosciences Enters into Agreement with Excivion 12
Lipoxen Enters Into Co-Development Agreement With SynBio 13
Lipoxen Extends Co-Development Agreement With IAVI 14
Licensing Agreements 15
Baxalta Enters into Licensing Agreement with Xenetic Biosciences 15
Serum Institute of India Enters into Licensing Agreement with Xenetic Biosciences 16
Equity Offering 17
Xenetic Biosciences Raises USD10 Million in Public Offering of Units 17
Lipoxen Completes Private Placement Of Shares For US$19.91 Million 19
Debt Offering 21
Xenetic Biosciences Raises USD3 Million in Private Placement of 10% Notes 21
Acquisition 22
OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 22
General Sales Completes Reverse Acquisition Transaction with Xenetic Biosciences 23
Xenetic Biosciences Completes Acquisition Of SymbioTec For US$14.4 Million 24
Xenetic Biosciences Inc – Key Competitors 25
Xenetic Biosciences Inc – Key Employees 26
Xenetic Biosciences Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Nov 15, 2017: Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update 28
Aug 15, 2017: Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update 30
May 16, 2017: Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update 32
Apr 03, 2017: Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update 33
Nov 15, 2016: Xenetic Biosciences Reports Third Quarter Financial Results and Provides Business Update 35
Corporate Communications 37
Oct 31, 2017: Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer 37
Aug 14, 2017: Xenetic Biosciences Announces Appointment of Three Directors to the Board 38
Apr 04, 2017: Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer 39
Jan 04, 2017: Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer 40
Dec 06, 2016: Xenetic Biosciences Expands Management Team with Key Appointment of Jeffrey F. Eisenberg as Chief Operating Officer 41
Dec 05, 2016: Xenetic Biosciences appoints new COO 42
Nov 22, 2016: Xenetic Biosciences appoints new board member 43
Nov 22, 2016: Xenetic Biosciences Appoints Edward J. Benz, Jr., M.D., Former Dana-Farber CEO, to its Board of Directors 44
Jul 11, 2016: Xenetic Biosciences Appoints Jeffrey F. Eisenberg to the Board of Directors 45
Feb 29, 2016: Xenetic Biosciences Appoints Renowned Chemist and Nobel Laureate, Dr. Roger D. Kornberg, to Board of Directors 46
Product News 47
Dec 01, 2016: Xenetic Biosciences to Present at the LD Micro 2016 Annual Conference 47
Sep 22, 2016: Xenetic Biosciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference 48
Apr 20, 2017: Xenetic Biosciences’ PolyXen Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston 49
Clinical Trials 50
Oct 10, 2016: Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen for Anemia 50
Apr 01, 2016: PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Vaccine Xemys for Multiple Sclerosis 51
Other Significant Developments 52
Mar 27, 2017: Xenetic Biosciences Provides Update on Patent Portfolio Development 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Xenetic Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Xenetic Biosciences Acquires Rights to Virexxa from Kevelt 11
Xenetic Biosciences Enters into Agreement with Excivion 12
Lipoxen Enters Into Co-Development Agreement With SynBio 13
Lipoxen Extends Co-Development Agreement With IAVI 14
Baxalta Enters into Licensing Agreement with Xenetic Biosciences 15
Serum Institute of India Enters into Licensing Agreement with Xenetic Biosciences 16
Xenetic Biosciences Raises USD10 Million in Public Offering of Units 17
Lipoxen Completes Private Placement Of Shares For US$19.91 Million 19
Xenetic Biosciences Raises USD3 Million in Private Placement of 10% Notes 21
OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 22
General Sales Completes Reverse Acquisition Transaction with Xenetic Biosciences 23
Xenetic Biosciences Completes Acquisition Of SymbioTec For US$14.4 Million 24
Xenetic Biosciences Inc, Key Competitors 25
Xenetic Biosciences Inc, Key Employees 26
Xenetic Biosciences Inc, Subsidiaries 27

★海外企業調査レポート[Xenetic Biosciences Inc (XBIO)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Blue Energy Ltd (BUL):石油・ガス:M&Aディール及び事業提携情報
    Summary Blue Energy Ltd (BEL) is an oil and gas company that provides exploration and development services. The company provides exploration and production of coal seam gas and conventional oil, and gas resources in Australia. Its projects portfolio includes carpentaria basin, bowen basin, galilee b …
  • Helix Resources Ltd (HLX):企業の財務・戦略的SWOT分析
    Summary Helix Resources Ltd (HRL) operates as a mining and mineral exploration company. The company carries out the business of identification, acquisition, and development of mineral properties. It explores gold, copper, zinc, uranium, nickel, and iron ore properties. HRL's projects include Colleri …
  • Kobe Steel Ltd:企業のM&A・事業提携・投資動向
    Kobe Steel Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kobe Steel Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • ImmunoGen Inc (IMGN):企業の財務・戦略的SWOT分析
    ImmunoGen Inc (IMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Massachusetts Eye and Ear Infirmary-製薬・医療分野:企業M&A・提携分析
    Summary Massachusetts Eye and Ear Infirmary (MEE) is a healthcare service provider that offers primary, medical and surgical care services. The hospital offers services through departments such as ophthalmology, otolaryngology and patient care services. Its patient care services include patient educ …
  • GenMark Diagnostics Inc (GNMK):企業の財務・戦略的SWOT分析
    Summary GenMark Diagnostics Inc (GenMark) is a medical device company that provides clinical testing systems. The company offers products such as XT-8 systems and ePlex systems. It offers pipeline products include eSensor 2C 19 genotyping test, eSensor HCV genotyping test, eSensor HCVg direct test, …
  • Shanghai Pharmaceutical Co Ltd (601607):企業の財務・戦略的SWOT分析
    Shanghai Pharmaceutical Co Ltd (601607) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Tompkins Financial Corp (TMP):企業の財務・戦略的SWOT分析
    Tompkins Financial Corp (TMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Sysco Corporation (SYY):企業の財務・戦略的SWOT分析
    Sysco Corporation (SYY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Genting Bhd (GENTING):企業の財務・戦略的SWOT分析
    Genting Bhd (GENTING) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Qiagen Marseille SA-医療機器分野:企業M&A・提携分析
    Summary Qiagen Marseille SA (HalioDx), formerly Ipsogen SA is a subsidiary of Qiagen NV, a drugs manufacturing company that develops and markets molecular diagnostic tests. The company offers products for the treatment of chronic myeloid, chronic lymphocytic, acute myeloid, and acute lymphoblastic l …
  • DNO ASA (DNO):企業の財務・戦略的SWOT分析
    Summary DNO ASA (DNO) is an oil and gas company that provides mineral properties exploration and development services. The company's services include selective and targeted drilling, fractured carbonate plays that are characteristic of the MENA region. It operates its oil and gas producing assets lo …
  • IXICO Plc (IXI):医療機器:M&Aディール及び事業提携情報
    Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints and assessing the safety and efficacy of drugs. The company offers products such as assessa, trial tracker, trialwire and mehealth. It provides web-based …
  • Probiogen AG-製薬・医療分野:企業M&A・提携分析
    Summary Probiogen AG (Probiogen), a subsidiary of Minapharm Pharmaceuticals & Chemical Industries is a contract development and manufacturing organization that offers cell line engineering, process development and GMP manufacturing of biopharmaceuticals. The organization’s services comprise therapeu …
  • Indeck Energy Services Inc:企業の戦略的SWOT分析
    Indeck Energy Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • China Development Bank:企業の戦略・SWOT・財務分析
    China Development Bank - Strategy, SWOT and Corporate Finance Report Summary China Development Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • BASF SE (BAS)-石油・ガス分野:企業M&A・提携分析
    Summary BASF SE (BASF) is a chemical company, which carries out research and development (R&D), production, marketing and sales of chemicals, plastics, crop protection products, and performance products. Its product line comprises solvents, adhesives, surfactant, organic chemicals, fuel additives, e …
  • Shanghai Desano Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Shanghai Desano Pharmaceutical Co Ltd (Desano) is a drug manufacturing company that manufactures, develops, and markets generic APIs. The company’s products include generic APIs of anti-retroviral, oncology and anti-malarial products. It also provides APIs and FPPs. Desano's API manufacturin …
  • Isagen SA ESP:企業の発電所・SWOT分析2018
    Isagen SA ESP - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • Qatar Electricity & Water Co QPSC (QEWS):企業の財務・戦略的SWOT分析
    Qatar Electricity & Water Co QPSC (QEWS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆